OMALIZUMAB — all Canadian products
13 DINs
13 marketed/approved
1 in shortage
Every Health Canada Drug Identification Number whose active ingredient is OMALIZUMAB, with holder, form, strength and current status, compared weekly against the Drug Product Database.
| DIN | Product | Company | Form | Route | Strength | Status | Shortage |
|---|---|---|---|---|---|---|---|
| 02553805 | OMLYCLO | CELLTRION INC. | Solution | Subcutaneous | OMALIZUMAB 75 MG | Marketed | |
| 02553813 | OMLYCLO | CELLTRION INC. | Solution | Subcutaneous | OMALIZUMAB 150 MG | Marketed | |
| 02561018 | OMLYCLO | CELLTRION INC. | Solution | Subcutaneous | OMALIZUMAB 75 MG | Marketed | |
| 02561026 | OMLYCLO | CELLTRION INC. | Solution | Subcutaneous | OMALIZUMAB 150 MG | Marketed | |
| 02565021 | OMLYCLO | CELLTRION INC. | Solution | Subcutaneous | OMALIZUMAB 300 MG | Approved | |
| 02565013 | OMLYCLO | CELLTRION INC. | Solution | Subcutaneous | OMALIZUMAB 300 MG | Approved | |
| 02260565 | XOLAIR | NOVARTIS PHARMACEUTICALS CANADA INC | Powder For Solution | Subcutaneous | OMALIZUMAB 150 MG | Marketed | |
| 02545160 | XOLAIR | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | Subcutaneous | OMALIZUMAB 300 MG | Marketed | |
| 02459787 | XOLAIR | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | Subcutaneous | OMALIZUMAB 75 MG | Marketed | |
| 02459795 | XOLAIR | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | Subcutaneous | OMALIZUMAB 150 MG | Marketed | |
| 02545136 | XOLAIR | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | Subcutaneous | OMALIZUMAB 75 MG | Marketed | |
| 02545144 | XOLAIR | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | Subcutaneous | OMALIZUMAB 150 MG | Marketed | Yes |
| 02545152 | XOLAIR | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | Subcutaneous | OMALIZUMAB 300 MG | Approved |
Browse other molecules: